Compound Screening Development In-Vivo Protein 
Drug Discovery World
OCTOBER 4, 2022
William Erhardt , President, Head of Development & Operations of biotech Oligomerix, tells Lu Rahman about the company’s differentiated approach to developing disease-modifying therapeutics for neurodegenerative diseases. . Overcoming sector challenges . In the US alone, AD prevalence is expected to increase from 6.5
Drug Discovery World
FEBRUARY 22, 2024
Libra Therapeutics is a San Diego-based biotech focused on developing novel disease-modifying therapeutics, which restore the cellular balance that is disrupted in neurodegenerative diseases. Libra’s pipeline targets mechanisms that can mitigate protein pathology associated with CNS degenerative disorders.
Drug Discovery World
AUGUST 15, 2023
Although such electrophysiological systems may be more predictive of potential cardiac safety and efficacy than non-functional binding assays, many apparently attractive new drugs are still being discontinued later in development. Unexpected late-stage failures in drug development are, of course, the costliest.
Expert insights. Personalized for you.
52 
Let's personalize your content